Surgery of the spine to fuse the vertebral bones is one of the most commonly performed operations with an estimated 350,000 Americans undergoing this surgery annually with estimated costs of $60 billion. Current procedures are highly invasive with limited success. The goal of this study is to develop a safe efficacious system for inducing spine fusion which will eliminate the need for invasive surgery. We have currently developed a cell based gene therapy system that can induce rapid bone formation at a targeted location which is independent of immune status of the model. This system relies on adenovirus transduced cells expressing bone morphogenetic protein 2 to induce bone formation leading to vertebral fusion after delivery into the paraspinous musculature. To prolong cell survival and insure cells are maintained at the target site, we have encapsulated them in a nondegradable hydrogel material. This provides additional safety by eliminating direct injection of the virus through cell delivery, and prevention of cell diffusion, through encapsulation. Here we provide preliminary data; demonstrating spine fusion using this system at 6 weeks after induction. This is the first step in demonstrating efficacy, a critical component of preclinical testing. Thus with validation of our hypothesis, this approach can now be developed as a safe and efficacious gene therapy system for spine fusion, thus circumventing the need for costly invasive surgery.

关键词：医药；治疗技术；基因治疗；脊柱融合

查看摘要 索取原文[33页]

The purpose of this study is to compare a brief-cognitive behavioral therapy (B-CBT) to usual care in the treatment of active duty Service Members who report suicidal ideation with intent to die or those who make a suicide attempt. Enrollment, assessment, and treatment of study participants continues as planned without problems. To date, 161 subjects have consented to participate, of whom 140 have been randomized. 3-, 6-, 12-, and 18-month assessments have been initiated. Recruitment is occurring at a fast pace, with target enrollment (i.e., 150 participants total) projected to be achieved within the next month.

关键词：医药；治疗技术；短暂认知行为疗法；B-CBT；军队

查看摘要 索取原文[8页]

The Wilms' tumor gene, WT1, encodes transcription factors that regulate cell proliferation, differentiation, and apoptosis. WT1 protein is highly expressed in malignant pleural mesothelioma (MPM), and is a rational target for immunotherapy. We have developed a vaccine comprised of four WT1 heteroclitic peptides that are given together with Montanide and GM-CSF as immunologic adjuvants. This WT1 vaccine was previously tested in a small pilot trial, and shown to be safe and immunogenic. We have chosen to test the efficacy of this vaccine in MPM patients who have minimal disease burden after completion of multimodality therapy, but remain at exceedingly high risk for recurrence. The specific aim of this project is to conduct a multicenter, blinded, randomized trial comparing treatment with the WT-1 peptide vaccine + Montanide/GM-CSF to treatment with Montanide/GM-CSF alone in patients with MPM who have completed multimodality therapy. The primary endpoint is progression free survival. The trial has opened at Memorial Sloan-Kettering and is actively enrolling patients.

关键词：医药；治疗技术；恶性胸膜间皮瘤；WT-1模拟肽疫苗

查看摘要 索取原文[5页]

Several in vitro studies have demonstrated the non-thermal.

关键词：医药；治疗技术；乳腺癌；高强度聚焦超声

查看摘要 索取原文[17页]

This report is a summary of our first year's work on the proposed research. During this period, our effort was focused on technological development for thermal ablation in mice. Our goal was to establish a small- animal MR-guided HIFU experimental system that enables simultaneous HIFU ablation and MR guidance. This goal was achieved and our experimental results demonstrated the basic function of the experimental system in in-vitro studies. We have laid the groundwork for the feasibility investigation of mouse tumor ablation in the second year. Based on the current progress, we will continue work on our technological improvement of MR-guided HIFU system for in-vivo studies. We believe this system will be ready for animal experiments after several further invitro studies in two or three months.

关键词：医药；治疗技术；肾血管肌脂肪瘤；HIFU治疗

查看摘要 索取原文[9页]

The aim of our research is to find novel targeted therapy for NF2 patients to provide a new therapeutic option for meningiomas that includes the standard of care radiotherapy. During the first year if this project we have successfully selected four small molecule compounds that preferentially inhibit NF2 mutant meningioma cells in vitro. These are FDA approved drugs that are safe for human use. We validated these drugs by using human cell lines and tested their ability to synergize with radiation. We have optimized the use of a CT-guided conformal radiation that can be tested in a meningioma mouse model. The findings obtained during the first year of this research project will be valuable for second phase, in which we will be testing combinatorial approaches in a meningioma mouse model.

关键词：医药；治疗技术；脑膜瘤；Nf2肿瘤抑制基因

查看摘要 索取原文[21页]

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

关键词：行业事件分析；竞争环境；竞争对手；行业数据

查看摘要 索取原文[21页]

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面进行了分析评论。

关键词：医药；政策环境；市场行情；厂商动态；科技研发；国际资讯；行业数据；分析评论

查看摘要 索取原文[81页]

本刊以七大战略性新兴产业——节能环保、新一代信息技术、生物、高端装备制造、新能源、新材料、新能源汽车为研究重点，关注国家高层和各部委的动态，剖析国家和地方的新兴产业政策。本刊设有政策导读、领导讲话、七大战略性新兴产业本周国内外行业动态和重点企业新闻、投资专题四大板块，能够实时监测新兴产业和重点企业动态，把握新兴产业发展方向，研究发展重点，寻求发展机遇。

关键词：节能环保；新一代信息技术；生物；高端装备制造；新能源；新材料；新能源汽车

查看摘要 索取原文[59页]

关键词：中医药；发展前景；基金

查看摘要 索取原文[1页]